Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
25.27 USD   +2.97%
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
21.51(c) 22.09(c) 23.53(c) 24.54(c) 25.27(c) Last
363 476 373 485 204 758 238 295 345 477 Volume
0.00% +2.70% +6.52% +4.29% +2.97% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -166 M - -
Net Debt 2022 - - -
P/E ratio 2022 -8,92x
Yield 2022 -
Sales 2023 3,33 M - -
Net income 2023 -170 M - -
Net Debt 2023 - - -
P/E ratio 2023 -9,01x
Yield 2023 -
Capitalization 1 474 M 1 474 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 442x
Nbr of Employees 89
Free-Float 85,6%
More Financials
Company
Vaxcyte Inc. is a clinical-stage vaccine company focused on developing vaccines to protect humankind from the consequences of bacterial diseases. The Company’s pipeline includes pneumococcal conjugate vaccine (PCV), VAX-24, VAX-XP, VAX-A1 and VAX-PG. The Company’s PCV candidates is in development, targeting global pneumococcal vaccine market. The Company’s lead vaccine candidate, VAX-24, is a 24-valent,... 
Read more
More about the company
Ratings of Vaxcyte, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D
More Ratings
All news about VAXCYTE, INC.
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
05/09Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
04/20INSIDER SELL : Vaxcyte
MT
04/18VAXCYTE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/12TRANSCRIPT : Vaxcyte, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2..
CI
04/07INSIDER SELL : Vaxcyte
MT
04/05Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference
AQ
04/04Vaxcyte Initiates Dosing in Second Part of Phase 1/2 Trial of VAX-24 in Invasive Pneumo..
MT
04/04Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinica..
GL
04/04Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 P..
CI
03/14INSIDER SELL : Vaxcyte
MT
More news
News in other languages on VAXCYTE, INC.
05/09Vaxcyte, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
04/07VENTE D'INITIÉS : Vaxcyte
04/04Vaxcyte commence à administrer la deuxième partie de l'essai de phase 1/2 du VAX-24 dan..
04/04Vaxcyte, Inc. annonce l'administration de doses aux premiers participants de la partie ..
02/28Vaxcyte, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre 2..
More news
Chart VAXCYTE, INC.
Duration : Period :
Vaxcyte, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VAXCYTE, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 25,27 $
Average target price 48,50 $
Spread / Average Target 91,9%
EPS Revisions
Managers and Directors
Grant E. Pickering Chief Executive Officer & Director
Andrew L. Guggenhime President & Chief Financial Officer
Carlos V. Paya Chairman
Romulo Colindres Chief Medical Officer
Jim Wassil Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
VAXCYTE, INC.6.22%1 431
GILEAD SCIENCES, INC.-12.99%78 068
REGENERON PHARMACEUTICALS, INC.5.71%70 575
VERTEX PHARMACEUTICALS19.24%65 005
WUXI APPTEC CO., LTD.-16.20%42 275
BIONTECH SE-41.35%36 745